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Partial versus total knee replacement for knee osteoarthritis
Triangulation of findings from several different study 
designs is important in the generation of the best 
broadly applicable and generalisable evidence to guide 
the delivery of efficacious and cost-effective health-
care interventions. David Beard and colleagues1 report 
in The Lancet an impressive randomised controlled 
trial that compared the outcomes of partial knee 
replacement (PKR) and total knee replacement 
(TKR) for treatment of isolated medial compartment 
osteoarthritis of the knee in 528 patients (42% female, 
mean age 65·0 years) who had an American Society 
of Anesthesiologists score of 1 or 2, an intact anterior 
cruciate ligament, and correctable varus deformity. In 
the TOPKAT study,2 Beard and colleagues employed a 
useful expertise-based and equipoise-based delivery 
unit design, which successfully facilitated recruitment 
after previous studies reported difficulty.
Before this study, data from large longitudinal 
datasets, such as registries, have reported a much higher 
cumulative probability of revision after PKR than after 
TKR, uncertainty regarding differences in patient-related 
outcomes between groups, and much lower early 
postoperative mortality with PKR.3–9 However, these 
studies have been subject to selection bias, and little 
was known of the relative cost-effectiveness of the two 
operations. A randomised controlled trial is thus timely 
and important. TOPKAT2 shows that both interventions 
provide a 5-year benefit for patients regarding 
Oxford Knee Score; no evidence of any difference was 
found between the groups (mean difference 1·04, 
95% CI –0·42 to 2·50; p=0·159), indicating that both 
interventions were clinically effective.
The trial was not powered to show the magnitude of 
difference in number of revisions that has previously been 
suggested by registries.2 The widely generalisable data 
obtained from the National Joint Registry for England, 
Wales, Northern Ireland, and the Isle of Man, which 
were recorded in the same location as this study, report 
5-year revision rates of 2·65% (95% CI 2·61–2·68) for 
TKR and 6·11% (5·94–6·29) for PKR.10 However, TOPKAT 
was only powered to detect a difference of more than 7% 
(which would equate to almost a 300% increase in the 
number of revisions between the two groups).
The health economics data are a welcome addition 
to our knowledge base, and they suggest improved 
cost-effectiveness with PKR. In TOPKAT’s within-trial 
cost-effectiveness analysis, PKR was found to be more 
effective (0·240 additional quality-adjusted life-years, 
95% CI 0·046 to 0·434) and less expensive (–£910, 
–1503 to –317) than TKR during the 5 years of follow-
up. Whether this trend will be sustained beyond 5 years 
remains to be seen. As more implants are revised over 
time, the relative cost-effectiveness could change; thus, 
we await the long-term results with interest. Beard and 
colleagues report the difference in cost-effectiveness as 
being partly due to increased outpatient attendance in 
the TKR group; however, the reasons for this increased 
attendance are not reported. Follow-up protocols are 
an area of interest and debate at present, particularly 
whether we should be reviewing postoperative 
arthroplasty patients as frequently as at present, 
and this trial further highlights the potential cost 
implications associated with this follow-up.
It is encouraging to see that the trial compared 
classes of knee replacement, rather than brands, and 
it is thus more likely to be generalisable. Surgeons 
undertaking PKR in the study had to be relatively high-
volume surgeons (performing more than ten surgeries 
per annum compared to the national median of five 
surgeries per annum, with an upper quartile of more 
than 13 surgeries per annum), which means that the 
results might not be fully generalisable but instead 
show what is attainable if surgery is undertaken by sub-
specialists.2,10 We note that the same strict requirement 
Published Online 
July 17, 2019 
http://dx.doi.org/10.1016/
S0140-6736(19)31612-5
See Online/Articles 
http://dx.doi.org/10.1016/
S0140-6736(19)31281-4
Jim
 V
ar
ne
y/
Sc
ie
nc
e 
Ph
ot
o 
Li
br
ar
y 
Comment
2 www.thelancet.com   Published online July 17, 2019   http://dx.doi.org/10.1016/S0140-6736(19)31612-5
for surgical experience far greater than the national 
median was not a requirement in the TKR group, and 
that the most frequently used brand of TKR, the LCS, is 
no longer available.
This valuable study adds strength to previous data, 
which suggested no difference in clinical outcomes 
between PKR and TKR.4 Although it is underpowered 
to show the marked differences in number of revisions 
or mortality shown by larger cohort studies, it adds 
important new evidence for the evaluation of the 
relative cost-effectiveness of these different operations 
in the first 5 years after surgery. In view of the results of 
the TOPKAT study, we agree that the potential benefits 
and drawbacks associated with PKR versus TKR should 
be discussed as part of the informed consent process 
with patients meeting the inclusion criteria for this 
trial. Further studies that use methods such as discrete 
choice experiments and qualitative methods to explore 
the lived experience of patients undergoing PKR and 
TKR could help patients and surgeons in the difficult 
choice between PKR and TKR in those patients who 
are suitable to receive either option. In the meantime, 
Beard and colleagues should be commended for 
the successful delivery of an important randomised 
controlled trial in arthroplasty, an area that has 
previously been notorious for the lack of such evidence 
and for the challenges of conducting randomised trials.
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